Buntanetap Safe, Effective in Phase 2a Trial; Annovis Plans More | Alzheimer's News Today
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today
